For the past 20 years, the quick development of biological therapeutics, like antibodies, CAR-T cell therapy, antibody-drug conjugates, etc., have played a significant role in treating several ...

First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...

As the use of immunoassays to discover, detect, and quantitate proteins from a variety of biological samples has greatly expanded, so have requirements for enhanced sensitivity, precision, reliability ...